Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations

被引:53
作者
Geisler, J [1 ]
Lonning, PE [1 ]
机构
[1] Haukeland Hosp, Dept Med, Sect Oncol, N-5021 Bergen, Norway
关键词
aromatase inhibitors; estrogens; breast cancer; anastrozole; letrozole; exemestane;
D O I
10.1016/j.jsbmb.2005.04.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The so-called "third-generation" aromatase inhibitors/inactivators have become standard first-line endocrine therapy for postmenopausal women in the metastatic setting. In addition, these compounds, administered as monotherapy or in sequence with tamoxifen, are likely to become standard adjuvant therapy in most countries in the near future. In contrast to the SERMs, aromatase inhibitors may be assessed for their biochemical efficacy in vivo either by measuring their ability to suppress plasma and tissue estrogen levels or, alternatively, by measuring their ability to inhibit the conversion of tracer-labelled androstenedione into estrone. While contemporary methods for estrogen measurement (with the exception of estrone sulphate) lack the sensitivity to measure plasma estrogen levels during treatment with the most potent compounds, in vivo aromatase inhibition can be determined with a much better sensitivity. Thus, in a joint program conducted by the Royal Marsden Hospital, London and our team in Bergen, we were able to reveal profound differences between first- and second-generation aromatase inhibitors, causing 50-90% aromatase inhibition, and the three third-generation compounds, causing > 98% inhibition of total body aromatization. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 55 条
[1]  
Baum M, 2002, LANCET, V359, P2131
[2]   The human CYP19 (aromatase P450) gene:: update on physiologic roles and genomic organization of promoters [J].
Bulun, SE ;
Sebastian, S ;
Takayama, K ;
Suzuki, T ;
Sasano, H ;
Shozu, M .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5) :219-224
[3]   Modulation of aromatase expression in human breast tissue [J].
Chen, SU ;
Zhou, DJ ;
Yang, C ;
Okubo, T ;
Kinoshita, Y ;
Yu, B ;
Kao, YC ;
Itoh, T .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 79 (1-5) :35-40
[4]   Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues [J].
Chetrite, GS ;
Cortes-Prieto, J ;
Philippe, JC ;
Wright, F ;
Pasqualini, JR .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2000, 72 (1-2) :23-27
[5]   A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].
Coombes, RC ;
Hall, E ;
Gibson, LJ ;
Paridaens, R ;
Jassem, J ;
Delozier, T ;
Jones, SE ;
Alvarez, I ;
Bertelli, G ;
Ortmann, O ;
Coates, AS ;
Bajetta, E ;
Dodwell, D ;
Coleman, RE ;
Fallowfield, LJ ;
Mickiewicz, E ;
Andersen, J ;
Lonning, PE ;
Cocconi, G ;
Stewart, A ;
Stuart, N ;
Snowdon, CF ;
Carpentieri, M ;
Massimini, G ;
Bliss, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092
[6]  
deJong PC, 1997, CANCER RES, V57, P2109
[7]  
DOWSETT M, 1987, CANCER RES, V47, P1957
[8]   Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer [J].
Dowsett, M ;
Doody, D ;
Miall, S ;
Howes, A ;
English, J ;
Coombes, RC .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 56 (01) :25-34
[9]  
Dowsett M, 1995, CLIN CANCER RES, V1, P1511
[10]   Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].
Ellis, MJ ;
Coop, A ;
Singh, B ;
Mauriac, L ;
Llombert-Cussac, A ;
Jänicke, F ;
Miller, WR ;
Evans, DB ;
Dugan, M ;
Brady, C ;
Quebe-Fehling, E ;
Borgs, M .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816